What is the appropriate management of hyperkalemia?

Management of Hyperkalemia

Immediately administer 10 mL of 10% intravenous calcium gluconate for any patient with ECG changes (peaked T waves, QRS widening) or severe hyperkalemia to stabilize cardiac membranes within 1-3 minutes, then shift potassium intracellularly with insulin/glucose and nebulized salbutamol, and initiate potassium binders early because temporary shifting agents cause rebound hyperkalemia within 2 hours. 1, 2

Acute Hyperkalemia Management

Immediate Cardiac Membrane Stabilization

• Give 10 mL of 10% IV calcium gluconate immediately for patients with ECG changes or markedly elevated potassium (typically ≥6.5 mEq/L or any level with ECG changes). 1, 2
• The effect begins within 1-3 minutes but does not lower total body potassium—it only protects the heart from arrhythmia. 1, 2
• Repeat the calcium dose in 5-10 minutes if ECG changes persist. 1, 2
• Maintain continuous ECG monitoring because ECG findings are variable and less sensitive than laboratory values for predicting complications. 1, 2

Intracellular Potassium Shift (Onset 30-60 Minutes)

• Administer 10 units IV regular insulin with 50 mL dextrose (D50W) to drive potassium into cells. 1, 2
• Always co-administer glucose with insulin to prevent hypoglycemia. 2
• Nebulize salbutamol 20 mg in 4 mL as an adjunctive agent for additional intracellular shift. 1, 2
• The effect of β-agonists lasts only 2-4 hours. 1, 2
• Reserve IV sodium bicarbonate for patients with concurrent metabolic acidosis, as it promotes urinary potassium excretion through increased distal sodium delivery. 1, 2

Critical Timing Consideration

• Rebound hyperkalemia typically occurs ~2 hours after insulin, salbutamol, and bicarbonate because these agents only shift potassium temporarily without removing it from the body. 1, 2
• Initiate potassium binders early (within the first 1-2 hours) to prevent rebound. 1, 2

Potassium Elimination Strategies

• Loop diuretics are appropriate for hypervolemic, non-oliguric patients with preserved renal function to increase urinary potassium excretion. 1, 2
• Hemodialysis is indicated for refractory acute hyperkalemia, oliguria, or end-stage renal disease. 1, 2
• Dialysis is the only method that definitively removes potassium from the body in patients without adequate renal function. 1

Chronic Hyperkalemia Management

First-Line: Newer Potassium Binders

Sodium Zirconium Cyclosilicate (SZC) is the preferred agent for rapid chronic management with onset as fast as 1 hour and high selectivity for potassium. 2

SZC Dosing

• Acute phase: 10 g three times daily for 48 hours. 2
• Maintenance: 5-15 g once daily, titrated to maintain serum potassium 3.5-5.0 mEq/L. 2
• Acts throughout the small and large intestines. 2
• Each 5 g dose contains ~400 mg sodium—monitor for edema in heart failure patients. 2
• Adverse effects include constipation, diarrhea, nausea, and mild-to-moderate edema. 2

Patiromer as Alternative

• Starting dose: 8.4 g once daily, titratable up to 25.2 g daily. 2
• Onset of potassium-lowering is ~7 hours via calcium-for-potassium exchange in the colon. 2
• Separate patiromer from other oral medications by at least 3 hours to avoid drug-binding interactions. 2
• Each 8.4 g dose provides ~1.6 g calcium—monitor for hypercalcemia. 2
• Common adverse effects include gastrointestinal discomfort and hypomagnesemia. 2

Avoid Sodium Polystyrene Sulfonate (SPS)

• SPS is linked to intestinal ischemia, colonic necrosis, and 33% mortality in affected patients. 2
• Efficacy is inconsistent with onset ranging from hours to days, and long-term safety data are lacking. 2
• Non-selective ion binding causes hypocalcemia and hypomagnesemia. 2

RAAS Inhibitor Management: The Critical Priority

Do not discontinue or reduce RAAS inhibitors for hyperkalemia—treat the hyperkalemia first with potassium binders to maintain the mortality benefit of optimal RAAS inhibition. 1, 2

Evidence-Based Approach

• Continuing RAAS inhibitors reduces mortality and major adverse cardiovascular events compared with discontinuation, even when kidney function declines. 2
• Maximum tolerated RAAS inhibitor therapy should be maintained whenever clinically indicated for heart failure, CKD, diabetes, or hypertension. 1, 2
• If hyperkalemia develops, initiate potassium binders rather than reducing the RAAS inhibitor dose. 2, 3
• Up to one-third of NYHA Class II-IV heart failure patients develop hyperkalemia (>5.0 mEq/L) on MRAs, yet clinical benefit persists even with modest potassium elevations. 1

After Acute Hyperkalemia Resolves

• Re-initiate any discontinued RAAS inhibitor once potassium normalizes. 1, 2
• Reassess serum potassium within one week of restarting or up-titrating. 1, 2
• Identify and remove other hyperkalemia contributors: NSAIDs, potassium supplements, salt substitutes, high-potassium diet. 1, 2
• Utilize newer potassium binders (patiromer or SZC) to enable optimal RAAS inhibitor dosing. 2, 3

Monitoring Strategy

Frequency of Potassium Checks

• Measure potassium within 7-10 days of initiating or up-titrating any RAAS inhibitor. 1, 2
• Increase monitoring frequency in patients with CKD, diabetes, heart failure, or prior hyperkalemia episodes. 1, 2
• Individualize monitoring based on comorbidities and medication regimen. 1

Thresholds and Interpretation

• Serum potassium ≥5.5 mEq/L is the widely accepted hyperkalemia threshold, though adverse outcomes occur at >5.0 mEq/L in heart failure and CKD populations. 1, 2
• Focus on rapid potassium fluctuations and overall clinical status rather than rigid numeric thresholds alone. 1, 2

Laboratory Considerations

• Exclude pseudohyperkalemia before initiating treatment: caused by fist clenching, hemolysis, delayed specimen processing, or thrombocytosis. 1, 2
• Plasma potassium values are 0.1-0.4 mEq/L lower than serum values due to platelet potassium release during clotting. 1, 2
• Potassium determination methods are not standardized—reference ranges vary between laboratories. 1

Common Pitfalls and Safety Alerts

• The most critical error is discontinuing RAAS inhibitors instead of treating hyperkalemia, which increases cardiovascular and renal mortality. 2, 3
• Rebound hyperkalemia occurs ~2 hours after temporary shifting agents—do not rely on insulin/salbutamol alone without initiating binders. 1, 2
• Never give insulin without glucose to prevent life-threatening hypoglycemia. 2
• Monitor calcium levels in patients on patiromer as hypercalcemia may be under-reported. 2
• Account for sodium content in SZC (400 mg per 5 g dose) when prescribing to heart failure patients at risk for volume overload. 2
• ECG changes are variable and insensitive—do not wait for ECG changes to treat severe hyperkalemia (≥6.5 mEq/L). 1, 2